VIVA Company News

Viva Biotech 2022 Appreciation Receptions Review

On October 14, 2022, Viva Biotech successfully held two "Appreciation Receptions" in both Boston and San Diego. The receptions attracted nearly 160 entrepreneurs, scientists, and partners in the biomedical field from those areas. The receptions focused on Viva's recent developments and highlighted innovative technologies. Several executives such as Dr. Zhixiong Ye, CSO of Viva Biotech, Mr. Simon Bury, Vice President and Global head of BD at SYNthesis, Dr. Jianguo Ma, Senior Vice Director of Viva Biotech and CEO of Langhua Pharmaceutical, Dr. Xueheng Cheng, CTO of Viva Biotech, and many other executives attended the receptions and shared their views and insights.

Boston venue

Viva Biotech provides one-stop integrated services to global innovative drug discovery companies from early-stage structure-based drug development to commercial drug delivery. We continue to improve our CRO services and have built complete PROTAC technology services based on our strong drug discovery platform, providing a full range of services from target protein preparation to preclinical candidates. On the CDMO side, we continue to strengthen our CMC services and actively expand our capacities. Through these receptions, we hope to inform our clients and partners on our latest progress to enhance mutual communication and cooperation and better promote the global innovative drug development.

San Diego venue

Viva Biotech Released 2022 Interim Results Report

On August 29, 2022, Viva Biotech (1873.HK) released its 2022 interim results report. During the period ended June 30, 2022 (the "Reporting Period"), the revenue of the Group increased to RMB1,108.7 million from RMB1,026.5 million for the corresponding period last year, representing a YoY increase of approximately 8.0%. The gross profit increased from RMB316.3 million for the corresponding period last year to RMB345.0 million, representing a YoY increase of approximately 9.1%. The Group's adjusted net profit reached RMB89.0 million.

As of June 30, 2022, the Company's revenue from CRO business increased by approximately 26.5% from RMB321.0 million for the corresponding period of last year to RMB406.0 million. the Company's order backlog amounted to approximately RMB1,150.0 million, representing an increase of approximately 35.6% from RMB848.0 million for the corresponding period of last year. the Group made great efforts to strengthen the strategic integration with Langhua Pharmaceutical. During the Reporting Period, Langhua Pharmaceutical's CDMO backlog orders of approximately RMB700.0 million will lay a solid foundation for business performance in the second half of the year. Meanwhile, the Group intensified the construction of chemistry, manufacturing and control ("CMC") R&D centers and continued to facilitate the layout and materialization of new production capacity. During the Reporting Period, Langhua Pharmaceutical's total available capacity reached 860 cubic meters. In respect of EFS, the Company achieved a partial exit from 1 portfolio project after the reporting period (July 2022) through a transfer of old shares. Currently, 8 portfolio companies have achieved full or partial exits, and there are nearly 11 projects with potential exits in the next 1-3 years. In addition, the company is actively applying for a fund manager license and plans to conduct investment incubation business in the future by establishing an external investment fund.

VIVA Linkedin

Research & Development Progress

US FDA Approval of IND for Q-1801 by QureBio.Ltd

QureBio Ltd. recently announced that the U.S. Food and Drug Administration has granted IND approval of Q-1801，a SIRPα/PD-L1 bi-specific antibody. Q-1801 is the first FDA-approved SIRPα/PD-L1 bi-specific antibody in the world. Approval of Q-1801, the second approved bispecific antibodies from QureBio.Ltd, has demonstrated its innovation capacity.

Triumvira Immunologics Announced Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco and Previously Presented Initial HER2-Positive Solid Tumor Clinical Data at ESMO

On October 19, Triumvira Immunologics (“Triumvira”) , a company focused on the development of novel, targeted autologous and allogeneic TCR-T Cell Therapeutics, a clinical-stage company focused on the treatment of solid tumors, announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, California, to manufacture the company's pipeline of cell therapy candidates. Triumvira expects the facility to be fully operational by 2023.

In September, Triumvira announced initial Phase 1/2 clinical data of TAC01-HER2 in HER2-positive solid tumors at the 2022 ESMO. The data showed that TAC01-HER2 was well tolerated in both dosing groups, and early signs of clinical activity were observed in the higher-dose group, with a disease control rate of 75%, including one partial ease.

Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors

On October 19, Domain Therapeutics (“Domain” or “the Company”) , a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), announced that its proprietary IO candidate, DT-9081, has cleared its clinical trial applications (CTA) by the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) in Belgium, enabling Domain to start its Phase I clinical trial. The first-in-human clinical trial is on track to initiate by the end of the year.

Research & Development Progress

ABM Therapeutics received IND approval by FDA for MEK inhibitor ABM-168

On October 12, ABM Therapeutics, a biopharmaceutical company that focuses on small molecule research and development of novel drugs for the treatment of brain cancers, announced that the U.S. Food and Drug Administration (FDA) has granted IND approval of ABM-168, a self-developed MEK1/2 inhibitor. This is also the second approved self-developed drug from ABM Therapeutics after ABM-1310. With this approval, ABM Therapeutics' upcoming Phase I clinical trial will recruit patients with advanced solid tumors, especially patients with concurrent brain metastases or primary brain tumors, aiming to explore the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-168 in such patients.

ABM Therapeutics Announced First Patient Dosed in Phase I Clinical Trial of ABM-1310 in China

On September 16, 2022, ABM Therapeutics announced that the first patient has been successfully dosed with ABM-1310 in a multi-center phase I clinical trial in China. ABM-1310, ABM Therapeutic's proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor. ABM-1310 phase I trial, conducted in China, is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-1310 in Chinese patients with BRAF V600X mutated advanced solid tumors.

AceLink Therapeutics Received Orphan Drug Designation for its Novel GCS inhibitor AL01211 for the Treatment of Fabry Disease

On September 7, 2022, AceLink Therapeutics, Inc. announced that they received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry Disease.AL01211 was selected based on its unique properties to effectively treat peripheral organs that Fabry disease affects by reducing the risk of off-target effects by preventing the crossing of the blood-brain barrier. AceLink Therapeutics, Inc. is an innovative biopharmaceutical company developing transformative therapies for genetic diseases.

Research & Development Progress

Regenacy Pharmaceuticals Announced Completion of Enrollment for their Phase 2 Study in Diabetic Peripheral Neuropathy

On August 24, 2022, Regenacy Pharmaceuticals Inc, a clinical-stage, biopharmaceutical company developing breakthrough treatments for diabetes and other peripheral neuropathies, announced completion of enrollment for the company's phase 2 study of ricolinostat, an oral selective deacetylase 6 (HDAC6) inhibitor for painful diabetic peripheral neuropathy (DPN).

Arthrosi Completed AR882 Renal Impairment Study and its Phase 2b Study Enrollment

On August 9, 2022, Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company focused on the treatment and management of gou, announced the completion of their renal impairment study that utilizes the lead compound, AR882. AR882 is a potent and selective uricosuric agent which has shown effectiveness in lowering serum urate in patients with normal renal function and in patients with mild to severe renal impairment.

On August 23, 2022, Arthrosi announced the completion of enrollment for its global Phase 2b clinical study of AR882 for the treatment of chronic gout. The study, which exceeded the initial target enrollment of 120 patients, is designed to evaluate the safety and efficacy of AR882 in chronic gout patients who meet ACR/EULAR gout classification.

Business Progress

Anji Pharma and Population Health Partners Entered into Strategic Collaboration to Jointly Address High Prevalence Human Disease

On October 19, Anji Pharmaceuticals and Population Health Partners announced that they have entered into a strategic collaboration, bringing together two complementary teams to jointly address high prevalence human diseases. PHP will work with Anji to support their portfolio and to advise on strategic and operational matters as they advance clinical assets. The initial focus of the Anji/PHP collaboration is to accelerate development of the two lead clinical assets in Anji's pipeline. ANJ900 (delayed-release metformin) is an investigational agent currently in Phase 3 trials to enable safe use of metformin in Type 2 diabetes patients with advanced chronic kidney disease (CKD). ANJ908 (pradigastat) is a novel DGAT1 inhibitor which has completed a successful Phase 2 study in patients with chronic idiopathic constipation (NCT04620161).

Business Progress

ABM Therapeutics Appoints Zane Yang, M.D. as Chief Medical Officer

On October 10, ABM Therapeutics announced the appointment of Dr. Zane Yang as the company's Chief Medical Officer (CMO) that will lead the overall management of ABM Therapeutics. Dr. Yang will oversee the planning and execution of ABM's global clinical development strategies and participate in the creation and implementation of the company's overall business and development strategies. Dr. Yang has a rich professional and academic background with extensive experience in clinical research and development and management.

F5 Therapeutics awarded First Servier FAST Discovery Award

On September 28, F5 Therapeutics was awarded the first Servier FAST Discovery Award. Winning this award means F5 stood out from 23 applications, indicating the industry's recognition of F5's innovative treatment methods in the field of biomedicine. "Servier FAST Discovery Award" is co-sponsored by Servier and the California Life Sciences Association (CLSA) to support early-stage life science companies using innovative approaches in areas designated by the group: oncology, auto-immune diseases, genetically driven neurodegenerative, and movement disorders.

F5 is transforming targeted protein degradation to advance drug discovery by utilizing the cell's normal protein regulation systems to remove disease-causing proteins that cannot be targeted by traditional approaches.

HAYA Therapeutics won the "TOP 100 Swiss Startup Award 2022" and was successfully selected for the "Soonicorn Club 2022"

On September 7, the "Top 100 Swiss Startup Award 2022," sponsored by Venturelab, was announced. HAYA Therapeutics was named TOP100 Swiss Startups' 8th Best Startup and came first in the Cardiovascular & Drug Discovery sectors. In addition, HAYA Therapeutics was recently included in the"SoonicornClub 2022", which names the top Swiss technology startups. The awards given demonstrate the industry's recognition of their potential in the field of biomedicine.

Business Progress

Viva Biotech and Zelixir Biotech Reached A Strategic Cooperation Agreement to Accelerate the Efficiency of Innovative Drug Discovery

On August 23, Zelixir Biotech and Viva Biotech signed a strategic cooperation agreement and formed a partnership. Based on the complementary nature of their respective businesses and technologies, the two parties have launched an in-depth collaboration on research related to high-throughput, AI-assisted drug design and the molecular discovery of new drugs.

Investment Progress

Regenacy Pharmaceuticals Announced $9.3 Million in Series B Financing

On August 24, Regenacy Pharmaceuticals Inc announced the closing of a $9.3 million Series B financing led by Cobro Ventures, with follow-on investors including Taiwania Capital Management Corporation, 3E Bioventures Capital, Yonjin Venture and others. Yonjin Venture and others.

About Viva Biotech

Listing Date
2019.05.09
Price (2022.11.17)
HKD 1.71
52 WK Range
HKD 1.16-5.93
Market Cap (2022.11.17)
HKD 3.31B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2022, Viva Biotech has provided drug R&D and production services to 1,947 biotech and pharmaceutical clients around the world. We have invested and incubated 90 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries
Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com